Drug Database
SO

sotalol

✓ Approved

Hyloris Pharmaceuticals SA · ADRB1 · 小分子

什么是 sotalol?

sotalol 是一种小分子,由Hyloris Pharmaceuticals SA研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

公司Hyloris Pharmaceuticals SA
药物类别小分子
分子靶点ADRB1, ADRB2, KCNH2
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

sotalol 作用于 3 个分子靶点:

ADRB1adrenoceptor beta 1 (B1AR, RHR)
ADRB2adrenoceptor beta 2 (ADRBR, B2AR)
KCNH2potassium voltage-gated channel subfamily H member 2 (ERG1, H-ERG)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

sotalol 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Cardiac disordersAtrial fibrillation✓ Approved

相关研究文献

PubMedAdvanced materials (Deerfield Beach, Fla.)2026-11-13

Semiconductor-Plasmon-Enabled Efficient Neodymium Electroluminescence in Lead-Free Perovskite Near-Infrared Light-Emitting Diodes.

Cheng Siqi S, Wang Tianyuan T, Xu Hanqi H, Shen Hong H et al.

Lanthanide-doped lead-free perovskite nanocrystals are promising candidates for near-infrared (NIR) optoelectronics, yet their performance is limited by inefficient exciton-to-lanthanide energy-transfer, surface non-radiative losses, and intrinsically slow 4f-4f radiative transitions. Here, we report highly efficient Cs3YCl6:Sb3+, Nd3+ nanocrystals enabling high-performance NIR photoluminescence and electroluminescence. The isolated [YCl6]3- octahedral framework confines excitons and facilitates efficient Sb3+-induced localized defect-state emission sensitization to Nd3+, leading to intense NIR emissions at 890, 1070, and 1350 nm with an ultra-high NIR photoluminescence quantum yield (PLQY) of 65.9% for Nd3+-based lead-free perovskite nanocrystals. Sotalol molecular passivation further suppresses surface non-radiative recombination and improves energy-transfer efficiency from 51.5% to 66.8%. Moreover, Cu2-xS is introduced as a semiconductor localized surface plasmon resonance layer, its broad NIR plasmonic absorption peak with a maximum near 1070 nm, overlaps well with the Nd3+ emission, thereby selectively accelerating the spontaneous radiative decay at 890 and 1070 nm by 4.1-and 9.2-fold, respectively. Consequently, the optimized NIR light-emitting diodes delivers a maximum external quantum efficiency (EQE) of 10.89%, a peak power density of 3.8 mW cm-2, and a T50 lifetime of 389 min, representing a breakthrough among various rare earths-doped NIR light-emitting diodes.

PMID 43023628
阅读全文 →
PubMedReviews in cardiovascular medicine2026-11-05

Outpatient Initiation of Sotalol: Reappraising Risk, Monitoring, and Modern Care Pathways.

Agarwal Rakesh R, Lypourlis Dimitrios D

Sotalol remains an important antiarrhythmic drug for rhythm control in atrial fibrillation and other supraventricular arrhythmias. However, sotalol is traditionally initiated in the inpatient setting because of concerns regarding QT prolongation and torsades de pointes. This practice is based on early observational data collected before the availability of contemporary risk stratification, standardized protocols, and modern rhythm monitoring technologies. Over the past two decades, evidence from observational studies using device-based monitoring, protocolized outpatient clinics, and remote electrocardiographic technologies has demonstrated low rates of malignant ventricular arrhythmias in carefully selected patients. These data also highlight the importance of longitudinal surveillance, as clinically relevant QT prolongation may occur beyond the conventional inpatient monitoring window. Thus, this review examines the pharmacologic basis of sotalol-related proarrhythmia, critically reassesses the rationale for inpatient initiation, synthesizes contemporary evidence supporting outpatient strategies in carefully selected patients with protocolized monitoring, and proposes a practical, risk-stratified framework for outpatient sotalol initiation while identifying key knowledge gaps that still require prospective validation.

PMID 42985564
阅读全文 →
PubMedJournal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology2026-11-02

Sotalol and flecainide dual therapy in a dog with paroxysmal atrial fibrillation.

Mishra S U SU, Seo J J

A four-year-old Doberman pinscher was diagnosed with atrial fibrillation (AF) and equivocal dilated cardiomyopathy phenotype. Electrical cardioversion (ECV) was performed following two weeks of amiodarone treatment; however, the dog developed recurrent AF within one week post ECV. Following two additional months of amiodarone therapy, the dog represented with sinus rhythm and new hepatopathy. In-hospital electrocardiographic monitoring identified paroxysmal AF during sleep. Amiodarone therapy was transitioned to sotalol therapy, which prevented further paroxysmal AF episodes. However, episodes of atypical AFL were frequently observed during sleep at follow-ups over five months. Flecainide was added to the sotalol therapy, and no further occurrence of AF or AFL was observed at follow-ups over 10 months. This report highlights that dogs may present with paroxysmal AF post ECV. When the paroxysmal AF is likely vagally mediated, sotalol and flecainide dual therapy may be effective in preventing further occurrence of AF and AFL.

PMID 42970992
阅读全文 →
PubMedClinical toxicology (Philadelphia, Pa.)2026-10-30

Cardiac toxicity and dysrhythmias in acute poisoning: a ten-year cohort study.

Berling Ingrid I, Jenkins Shane S, Isbister Geoffrey K GK

Cardiac toxicity is frequently cited as an important cause of morbidity and mortality following acute drug overdose. The true incidence of direct drug related clinically significant cardiac complications and malignant dysrhythmias in more recent toxicology practice remains poorly defined. We aim to determine the frequency, nature, and outcomes of cardiac complications in patients presenting with acute poisoning. We conducted a retrospective analysis of a prospectively maintained clinical toxicology database over a 10-year period. Patients with acute poisoning managed by a specialist toxicology service were included. Cardiac complications were defined as hypotension (systolic blood pressure <90 mmHg) or a primary cardiac dysrhythmia considered temporally related to the poisoning. Sinus tachycardia was excluded. Demographics, exposures, treatments, and outcomes were extracted. A total of 9,743 poisoning presentations were included. Cardiac complications occurred in 473 patients (4.9%). Hypotension occurred in 368 patients (3.8%), primary dysrhythmias in 164 patients (1.7%), and both hypotension and dysrhythmia in 59 patients (0.6%). Most dysrhythmias were isolated bradycardia (139/164, 85%), commonly associated with clonidine (40%) and beta-blocker/calcium channel blocker poisoning (35%). Only 25 patients (0.3% of all poisoning presentations) developed primary dysrhythmias: atrial dysrhythmias (3), conduction abnormalities/delays (10), ectopic rhythms (5), asystole (1) or ventricular dysrhythmias (6; 0.06%). Malignant ventricular dysrhythmias occurred in six patients and were associated with sotalol, methadone, escitalopram, dothiepin, and nortriptyline poisoning. Twenty-one deaths occurred during the study period, but no death was attributable to a primary dysrhythmia temporally related to poisoning.Discussion: In this large cohort of almost 10,000 poisoning presentations, cardiac complications occurred in approximately one in twenty patients. However, almost 95% of these were either hypotension or isolated bradycardia. Only six patients (0.06%) had ventricular dysrhythmias. Our findings support previous studies demonstrating that clinically significant ventricular dysrhythmias are uncommon among unselected populations presenting with acute poisoning. We found that only a few individual drugs, such as sotalol, methadone, tricyclic antidepressants, and escitalopram, were associated with ventricular dysrhythmias, and that such events were rare overall. Cardiac effects occur in approximately 5% of acute poisoning presentations but are predominantly hypotension or sinus bradycardia. Clinically significant ventricular and supraventricular dysrhythmias are uncommon, occurring in less than 0.3% of cases. Death directly attributable to a primary poisoning-related dysrhythmia is rare.

PMID 42961000
阅读全文 →
PubMedFrontiers in cardiovascular medicine2026-10-28

Factors associated with mortality in patients with atrial fibrillation: an umbrella review of systematic reviews and meta-analyses.

Luo Jin J, Niu Yunpu Y, Ni Ming M, Zhang Jingyu J et al.

This study synthesized published meta-analyses to assess the quality, bias, and strength of evidence regarding mortality risk factors in patients with atrial fibrillation (AF). Web of Science, Embase, PubMed, and Cochrane database were used to search the literature up to May 2025. Eligible studies were systematic reviews or meta-analyses investigating AF-related mortality risk factors. AMSTAR tool was used to assess methodological quality and GRADE was used to evaluate evidence certainty. A total of 216 risk factors were identified. Among them, 86 showed significant associations with mortality, while 130 did not. Based on GRADE ratings, 11 were high-quality significant factors, and 9 were of moderate-quality. Factors linked to increased mortality included certain medications (digoxin, dronedarone, sotalol; warfarin/VKA vs. NOAC was associated with higher mortality), comorbidities (cancer, COPD, diabetes, anemia, frailty, LVH, peripheral artery disease), demographic characteristics (older age, smoking, BMI <18.5, Latin American ethnicity), and AF subtype (persistent or non-paroxysmal). In contrast, reduced mortality was associated with NOAC or DOAC use, higher BMI (25-30 or ≥30), surgical interventions (catheter ablation, LAAC/LAAO), other medications (SGLT2 inhibitors, statins), and early rhythm control. This review highlights key factors associated with mortality in AF. Increased risk was observed with warfarin/VKA use (vs. NOAC), certain antiarrhythmic drugs, comorbidities, low BMI, older age, smoking, and non-paroxysmal AF. In contrast, NOAC use, surgical interventions, high BMI, statin and SGLT2 inhibitor therapy, and early rhythm-control strategies were linked to reduced mortality risk.Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024533372, PROSPERO CRD42024533372.

PMID 42947670
阅读全文 →
PubMedPrenatal diagnosis2026-10-15

Transplacental Flecainide and/or Digoxin for Fetal Tachyarrhythmias: Therapeutic Efficacy and Clinical Experience.

Darakamas Mukpradab M, Anuwutnavin Sanitra S, Tongprasert Fuanglada F, Chankhunaphas Wisit W et al.

To assess the efficacy and safety of transplacental flecainide and/or digoxin for fetal tachyarrhythmias when sotalol is unavailable. We evaluated transplacental flecainide, digoxin, or combination therapy in a retrospective and prospective cohort across two Thai tertiary centers. Outcomes were classified as complete cardioversion, partial response (rate control), or treatment failure. Of 24 eligible pregnancies, 14 (58.3%) had supraventricular tachycardia (SVT), 8 (33.3%) had atrial flutter (AFL), and 2 (8.3%) had ventricular tachycardia (VT). Overall, clinical responses occurred in 91.7% (22/24) of fetuses. Flecainide monotherapy achieved 100% (9/9) complete cardioversion in SVT, compared with 50% (1/2) for digoxin. SVT combination therapy (n = 3) yielded 1 complete and 1 partial response. Among 7 flecainide-treated AFL cases, 5 (71.4%) achieved rate control and 2 (28.6%) achieved cardioversion; one digoxin-treated case fully converted. Flecainide resolved 1 of 2 VT cases (50%). Response rates were unaffected by hydrops, gestational age, or cardiac defects (p = 0.087-1.000). Maternal adverse events were mild and required no treatment discontinuation. Transplacental flecainide demonstrates high efficacy in SVT and effective rate control with preserved cardiac function in AFL. Its favorable safety profile makes it a practical alternative for first-line therapy where sotalol is unavailable and flecainide monitoring is infeasible.

PMID 42879820
阅读全文 →

注册免费账户还可查看另外 3061 篇文献

免费注册查看全部文献 →

了解更多sotalol